RCAN1 knockout and overexpression recapitulate an ensemble of rest-activity and circadian disruptions characteristic of Down syndrome, Alzheimer’s disease, and normative aging

Springer Science and Business Media LLC - Tập 14 Số 1 - 2022
Helen Wong1, Jordan M. Buck1, Curtis Borski1, Jessica Pafford2, Bailey N. Keller1, Ryan Milstead1, Jessica L. Hanson2, Jerry A. Stitzel1, Charles A. Hoeffer2
1Institute for Behavioral Genetics, University of Colorado Boulder, 1480 30th Street, Boulder, CO, 80309-0447, USA
2Department of Integrative Physiology, University of Colorado, Boulder, CO, 80303, USA

Tóm tắt

Abstract Background Regulator of calcineurin 1 (RCAN1) is overexpressed in Down syndrome (DS), but RCAN1 levels are also increased in Alzheimer’s disease (AD) and normal aging. AD is highly comorbid among individuals with DS and is characterized in part by progressive neurodegeneration that resembles accelerated aging. Importantly, abnormal RCAN1 levels have been demonstrated to promote memory deficits and pathophysiology that appear symptomatic of DS, AD, and aging. Anomalous diurnal rest-activity patterns and circadian rhythm disruptions are also common in DS, AD, and aging and have been implicated in facilitating age-related cognitive decline and AD progression. However, no prior studies have assessed whether RCAN1 dysregulation may also promote the age-associated alteration of rest-activity profiles and circadian rhythms, which could in turn contribute to neurodegeneration in DS, AD, and aging. Methods The present study examined the impacts of RCAN1 deficiency and overexpression on the photic entrainment, circadian periodicity, intensity and distribution, diurnal patterning, and circadian rhythmicity of wheel running in young (3–6 months old) and aged (9–14 months old) mice of both sexes. Results We found that daily RCAN1 levels in the hippocampus and suprachiasmatic nucleus (SCN) of light-entrained young mice are generally constant and that balanced RCAN1 expression is necessary for normal circadian locomotor activity rhythms. While the light-entrained diurnal period was unaltered, RCAN1-null and RCAN1-overexpressing mice displayed lengthened endogenous (free-running) circadian periods like mouse models of AD and aging. In light-entrained young mice, RCAN1 deficiency and overexpression also recapitulated the general hypoactivity, diurnal rest-wake pattern fragmentation, and attenuated amplitudes of circadian activity rhythms reported in DS, preclinical and clinical AD, healthily aging individuals, and rodent models thereof. Under constant darkness, RCAN1-null and RCAN1-overexpressing mice displayed altered locomotor behavior indicating circadian clock dysfunction. Using the Dp(16)1Yey/+ (Dp16) mouse model for DS, which expresses three copies of Rcan1, we found reduced wheel running activity and rhythmicity in both light-entrained and free-running young Dp16 mice like young RCAN1-overexpressing mice. Critically, these diurnal and circadian deficits were rescued in part or entirely by restoring Rcan1 to two copies in Dp16 mice. We also found that RCAN1 deficiency but not RCAN1 overexpression altered protein levels of the clock gene Bmal1 in the SCN. Conclusions Collectively, this study’s findings suggest that both loss and aberrant gain of RCAN1 precipitate anomalous light-entrained diurnal and circadian activity patterns emblematic of DS, AD, and possibly aging.

Từ khóa


Tài liệu tham khảo

Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013;80:1778–83.

Lott IT, Head E. Down syndrome and Alzheimer’s disease: a link between development and aging. Ment Retard Dev Disabil Res Rev. 2001;7:172–8.

Perluigi M, Pupo G, Tramutola A, Cini C, Coccia R, Barone E, et al. Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. Bioch Biophys Acta (BBA) - Mol Basis Dis. 2014;1842:1144–53.

Sun X, Wu Y, Chen B, Zhang Z, Zhou W, Tong Y, et al. Regulator of calcineurin 1 (RCAN1) facilitates neuronal apoptosis through caspase-3 activation. J Biol Chem. 2011;286:9049–62.

Wu Y, Song W. Regulation of RCAN1 translation and its role in oxidative stress-induced apoptosis. FASEB J. 2013;27:208–21.

Harris CD, Ermak G, Davies KJA. RCAN1-1L is overexpressed in neurons of Alzheimer’s disease patients. FEBS J. 2007;274:1715–24.

Wong H, Levenga J, Cain P, Rothermel B, Klann E, Hoeffer C. RCAN1 overexpression promotes age-dependent mitochondrial dysregulation related to neurodegeneration in Alzheimer’s disease. Acta Neuropathol. 2015;130:829–43.

Cook CN, Hejna MJ, Magnuson DJ, Lee JM. Expression of calcipressin1, an inhibitor of the phosphatase calcineurin, is altered with aging and Alzheimer’s disease. JAD. 2005;8:63–73.

Lin K, Tang M, Guo Y, Han H, Lin Y. Two polymorphisms of RCAN1 gene associated with Alzheimer’s disease in the Chinese Han population. East Asian Arch Psychiatry. 2011;21:79–84.

Lloret A, Badia M-C, Giraldo E, Ermak G, Alonso M-D, Pallardó FV, et al. Amyloid-β toxicity and tau hyperphosphorylation are linked via RCAN1 in Alzheimer’s disease. JAD. 2011;27:701–9.

Wu Y, Deng Y, Zhang S, Luo Y, Cai F, Zhang Z, et al. Amyloid-β precursor protein facilitates the regulator of calcineurin 1-mediated apoptosis by downregulating proteasome subunit α type-5 and proteasome subunit β type-7. Neurobiol Aging. 2015;36:169–77.

Wang T, Liu H, Wang Y, Liu C, Sun X. RCAN1 increases Aβ generation by promoting N-glycosylation via oligosaccharyltransferase. Curr Alzheimer Res. 2014;11:332–9.

Lee S, Bang SM, Hong YK, Lee JH, Jeong H, Park SH, et al. The calcineurin inhibitor Sarah (Nebula) exacerbates Aβ42 phenotypes in a Drosophila model of Alzheimer’s disease. Dis Model Mech. 2016;9:295–306.

Ermak G, Sojitra S, Yin F, Cadenas E, Cuervo AM, Davies KJA. Chronic expression of RCAN1-1L protein induces mitochondrial autophagy and metabolic shift from oxidative phosphorylation to glycolysis in neuronal cells. J Biol Chem. 2012;287:14088–98.

Ma H, Xiong H, Liu T, Zhang L, Godzik A, Zhang Z. Aggregate formation and synaptic abnormality induced by DSCR1. J Neurochem. 2004;88:1485–96.

Bhoiwala DL, Koleilat I, Qian J, Beyer B, Hushmendy SF, Mathew A, et al. Overexpression of RCAN1 isoform 4 in mouse neurons leads to a moderate behavioral impairment. Neurol Res. 2013;35:79–89.

Dierssen M, Arqué G, McDonald J, Andreu N, Martínez-Cué C, Flórez J, et al. Behavioral characterization of a mouse model overexpressing DSCR1/RCAN1. PLoS One. 2011;6:e17010.

Martin KR, Corlett A, Dubach D, Mustafa T, Coleman HA, Parkington HC, et al. Over-expression of RCAN1 causes Down syndrome-like hippocampal deficits that alter learning and memory. Hum Mol Genet. 2012;21:3025–41.

Hoeffer CA, Dey A, Sachan N, Wong H, Patterson RJ, Shelton JM, et al. The Down syndrome critical region protein RCAN1 regulates long-term potentiation and memory via inhibition of phosphatase signaling. J Neurosci. 2007;27:13161–72.

Chang KT, Shi Y-J, Min K-T. The Drosophila homolog of Down’s syndrome critical region 1 gene regulates learning: implications for mental retardation. Proc Natl Acad Sci. 2003;100:15794–9.

Kondratova AA, Dubrovsky YV, Antoch MP, Kondratov RV. Circadian clock proteins control adaptation to novel environment and memory formation. Aging. 2010;2:285–97.

Kwapis JL, Alaghband Y, Kramár EA, López AJ, Vogel Ciernia A, White AO, et al. Epigenetic regulation of the circadian gene Per1 contributes to age-related changes in hippocampal memory. Nat Commun. 2018;9:3323.

Smarr BL, Jennings KJ, Driscoll JR, Kriegsfeld LJ. A time to remember: the role of circadian clocks in learning and memory. Behav Neurosci. 2014;128:283–303.

Banks G, Heise I, Starbuck B, Osborne T, Wisby L, Potter P, et al. Genetic background influences age-related decline in visual and nonvisual retinal responses, circadian rhythms, and sleep. Neurobiol Aging. 2015;36:380–93.

Duffy JF, Zitting K-M, Chinoy ED. Aging and circadian rhythms. Sleep Med Clin. 2015;10:423–34.

Nakamura TJ, Nakamura W, Yamazaki S, Kudo T, Cutler T, Colwell CS, et al. Age-related decline in circadian output. J Neurosci. 2011;31:10201–5.

Wang JL, Lim AS, Chiang W-Y, Hsieh W-H, Lo M-T, Schneider JA, et al. Suprachiasmatic neuron numbers and rest-activity circadian rhythms in older humans: SCN and rest-activity rhythms. Ann Neurol. 2015;78:317–22.

Bonanni E, Maestri M, Tognoni G, Fabbrini M, Nucciarone B, Manca ML, et al. Daytime sleepiness in mild and moderate Alzheimer’s disease and its relationship with cognitive impairment. J Sleep Res. 2005;14:311–7.

Hatfield CF. Disrupted daily activity/rest cycles in relation to daily cortisol rhythms of home-dwelling patients with early Alzheimer’s dementia. Brain. 2004;127:1061–74.

Lim ASP, Kowgier M, Yu L, Buchman AS, Bennett DA. Sleep fragmentation and the risk of incident Alzheimer’s disease and cognitive decline in older persons. Sleep. 2013;36:1027–32.

Satlin A, Volicer L, Stopa EG, Harper D. Circadian locomotor activity and core-body temperature rhythms in Alzheimer’s disease. Neurobiol Aging. 1995;16:765–71.

Tranah GJ, Blackwell T, Stone KL, Ancoli-Israel S, Paudel ML, Ensrud KE, et al. Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Ann Neurol. 2011;70:722–32.

Weissová K, Bartoš A, Sládek M, Nováková M, Sumová A. Moderate changes in the circadian system of Alzheimer’s disease patients detected in their home environment. PLoS One. 2016;11:e0146200.

Ambrée O, Touma C, Görtz N, Keyvani K, Paulus W, Palme R, et al. Activity changes and marked stereotypic behavior precede Abeta pathology in TgCRND8 Alzheimer mice. Neurobiol Aging. 2006;27:955–64.

Leng Y, Musiek ES, Hu K, Cappuccio FP, Yaffe K. Association between circadian rhythms and neurodegenerative diseases. Lancet Neurol. 2019;18:307–18.

Musiek ES, Bhimasani M, Zangrilli MA, Morris JC, Holtzman DM, Ju Y-ES. Circadian rest-activity pattern changes in aging and preclinical Alzheimer disease. JAMA Neurol. 2018;75:582.

Wisor JP, Edgar DM, Yesavage J, Ryan HS, McCormick CM, Lapustea N, et al. Sleep and circadian abnormalities in a transgenic mouse model of Alzheimer’s disease: a role for cholinergic transmission. Neuroscience. 2005;131:375–85.

Bassell JL, Phan H, Leu R, Kronk R, Visootsak J. Sleep profiles in children with Down syndrome. Am J Med Genet. 2015;167:1830–5.

Ekstein S, Glick B, Weill M, Kay B, Berger I. Down syndrome and attention-deficit/hyperactivity disorder (ADHD). J Child Neurol. 2011;26:1290–5.

Fernandez F, Nyhuis CC, Anand P, Demara BI, Ruby NF, Spanò G, et al. Young children with Down syndrome show normal development of circadian rhythms, but poor sleep efficiency: a cross-sectional study across the first 60 months of life. Sleep Med. 2017;33:134–44.

Vicari S. Motor development and neuropsychological patterns in persons with Down syndrome. Behav Genet. 2006;36:355–64.

Stern AL, Naidoo N. Wake-active neurons across aging and neurodegeneration: a potential role for sleep disturbances in promoting disease. SpringerPlus. 2015;4:25.

Yin M, Chen Y, Zheng H, Pu T, Marshall C, Wu T, et al. Assessment of mouse cognitive and anxiety-like behaviors and hippocampal inflammation following a repeated and intermittent paradoxical sleep deprivation procedure. Behav Brain Res. 2017;321:69–78.

Zhao H-Y, Wu H-J, He J-L, Zhuang J-H, Liu Z-Y, Huang L-Q, et al. Chronic sleep restriction induces cognitive deficits and cortical beta-amyloid deposition in mice via BACE1-antisense activation. CNS Neurosci Ther. 2017;23:233–40.

Chauhan R, Chen K-F, Kent BA, Crowther DC. Central and peripheral circadian clocks and their role in Alzheimer’s disease. Dis Model Mech. 2017;10:1187–99.

Krishnan N, Rakshit K, Chow ES, Wentzell JS, Kretzschmar D, Giebultowicz JM. Loss of circadian clock accelerates aging in neurodegeneration-prone mutants. Neurobiol Dis. 2012;45:1129–35.

Minakawa EN, Miyazaki K, Maruo K, Yagihara H, Fujita H, Wada K, et al. Chronic sleep fragmentation exacerbates amyloid β deposition in Alzheimer’s disease model mice. Neurosci Lett. 2017;653:362–9.

Van Egroo M, Narbutas J, Chylinski D, Villar González P, Maquet P, Salmon E, et al. Sleep–wake regulation and the hallmarks of the pathogenesis of Alzheimer’s disease. Sleep. 2019;42:zsz017.

Kweon SH, Lee J, Lim C, Choe J. High-amplitude circadian rhythms in Drosophila driven by calcineurin-mediated post-translational control of sarah. Genetics. 2018;209:815–28.

Dyar KA, Ciciliot S, Tagliazucchi GM, Pallafacchina G, Tothova J, Argentini C, et al. The calcineurin-NFAT pathway controls activity-dependent circadian gene expression in slow skeletal muscle. Mol Metab. 2015;4:823–33.

Huang CC-Y, Ko ML, Vernikovskaya DI, Ko GY-P. Calcineurin serves in the circadian output pathway to regulate the daily rhythm of L-type voltage-gated calcium channels in the retina. J Cell Biochem. 2012;113:911–22.

Katz M, Simonetta S, Ralph M, Golombek D. Immunosuppressant calcineurin inhibitors phase shift circadian rhythms and inhibit circadian responses to light. Pharmacol Biochem Behav. 2008;90:763–8.

Nakai Y, Horiuchi J, Tsuda M, Takeo S, Akahori S, Matsuo T, et al. Calcineurin and its regulator Sra/DSCR1 are essential for sleep in Drosophila. J Neurosci. 2011;31:12759–66.

Rotter D, Grinsfelder DB, Parra V, Pedrozo Z, Singh S, Sachan N, et al. Calcineurin and its regulator, RCAN1, confer time-of-day changes in susceptibility of the heart to ischemia/reperfusion. J Mol Cell Cardiol. 2014;74:103–11.

Ruby NF, Fernandez F, Zhang P, Klima J, Heller HC, Garner CC. Circadian locomotor rhythms are normal in Ts65Dn “Down Syndrome” mice and unaffected by pentylenetetrazole. J Biol Rhythms. 2010;25:63–6.

Stewart LS, Persinger MA, Cortez MA, Snead OC. Chronobiometry of behavioral activity in the Ts65Dn model of Down syndrome. Behav Genet. 2007;37:388–98.

Heise I, Fisher SP, Banks GT, Wells S, Peirson SN, Foster RG, et al. Sleep-like behavior and 24-h rhythm disruption in the Tc1 mouse model of Down syndrome: sleep and rhythm disruption in Tc1 mice. Genes Brain Behav. 2015;14:209–16.

Levenga J, Peterson DJ, Cain P, Hoeffer CA. Sleep behavior and EEG oscillations in aged Dp(16)1Yey/+ mice: a Down syndrome model. Neuroscience. 2018;376:117–26.

Vega RB, Rothermel BA, Weinheimer CJ, Kovacs A, Naseem RH, Bassel-Duby R, et al. Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy. Proc Natl Acad Sci. 2003;100:669–74.

Jud C, Schmutz I, Hampp G, Oster H, Albrecht U. A guideline for analyzing circadian wheel-running behavior in rodents under different lighting conditions. Biol Proced Online. 2005;7:101–16.

Buck JM, Sanders KN, Wageman CR, Knopik VS, Stitzel JA, O’Neill HC. Developmental nicotine exposure precipitates multigenerational maternal transmission of nicotine preference and ADHD-like behavioral, rhythmometric, neuropharmacological, and epigenetic anomalies in adolescent mice. Neuropharmacology. 2019;149:66–82.

Levenga J, Wong H, Milstead R, LaPlante L, Hoeffer CA. Immunohistological examination of AKT isoforms in the brain: cell-type specificity that may underlie AKT’s role in complex brain disorders and neurological disease. Cereb Cortex Commun. 2021;2:tgab036.

Shoji H, Takao K, Hattori S, Miyakawa T. Age-related changes in behavior in C57BL/6J mice from young adulthood to middle age. Mol Brain. 2016;9:11.

Bishop NA, Lu T, Yankner BA. Neural mechanisms of ageing and cognitive decline. Nature. 2010;464:529–35.

Lott IT. Neurological phenotypes for Down syndrome across the life span. Prog Brain Res. 2012;197:101–21.

Pater C. Mild cognitive impairment (MCI) - the novel trend of targeting Alzheimer’s disease in its early stages - methodological considerations. Curr Alzheimer Res. 2011;8:798–807.

Duncan MJ. Interacting influences of aging and Alzheimer’s disease on circadian rhythms. Eur J Neurosci. 2020;51:310–25.

Fernandez F, Edgin JO. Poor sleep as a precursor to cognitive decline in Down syndrome: a hypothesis. J Alzheimers Dis Parkinsonism. 2013;3:124.

Sangoram AM, Saez L, Antoch MP, Gekakis N, Staknis D, Whiteley A, et al. Mammalian circadian autoregulatory loop: a timeless ortholog and mPer1 interact and negatively regulate CLOCK-BMAL1-induced transcription. Neuron. 1998;21:1101–13.

Wyse CA, Coogan AN. Impact of aging on diurnal expression patterns of CLOCK and BMAL1 in the mouse brain. Brain Res. 2010;1337:21–31.

Dierssen M, Arqué G, McDonald J, Andreu N, Martínez-Cué C, Flórez J, et al. Behavioral characterization of a mouse model overexpressing DSCR1/ RCAN1. PLoS One. 2011;6:e17010.

Hoeffer CA, Wong H, Cain P, Levenga J, Cowansage KK, Choi Y, et al. Regulator of calcineurin 1 modulates expression of innate anxiety and anxiogenic responses to selective serotonin reuptake inhibitor treatment. J Neurosci. 2013;33:16930–44.

Belichenko PV, Kleschevnikov AM, Becker A, Wagner GE, Lysenko LV, Yu YE, et al. Down syndrome cognitive phenotypes modeled in mice trisomic for all HSA 21 homologues. PLoS One. 2015;10:e0134861.

Faizi M, Bader PL, Tun C, Encarnacion A, Kleschevnikov A, Belichenko P, et al. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiol Dis. 2011;43:397–413.

Kleschevnikov AM, Belichenko PV, Gall J, George L, Nosheny R, Maloney MT, et al. Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis. 2012;45:683–91.

Stevanovic K, Yunus A, Joly-Amado A, Gordon M, Morgan D, Gulick D, et al. Disruption of normal circadian clock function in a mouse model of tauopathy. Exp Neurol. 2017;294:58–67.

Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, et al. Tau and Ab imaging, CSF measures, and cognition in Alzheimer’s disease. Sci Transl Med. 2016;8:10.

Buhl E, Higham JP, Hodge JJL. Alzheimer’s disease-associated tau alters Drosophila circadian activity, sleep and clock neuron electrophysiology. Neurobiol Dis. 2019;130:104507.

Liu Q, Busby JC, Molkentin JD. Interaction between TAK1–TAB1–TAB2 and RCAN1–calcineurin defines a signalling nodal control point. Nat Cell Biol. 2009;11:154–61.

Keating DJ, Dubach D, Zanin MP, Yu Y, Martin K, Zhao Y-F, et al. DSCR1/RCAN1 regulates vesicle exocytosis and fusion pore kinetics: implications for Down syndrome and Alzheimer’s disease. Hum Mol Genet. 2008;17:1020–30.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 14 Số 1

Thông tin tác giả